Inorganic Chemistry for Health: New Antidotes and Leishmaniasis Treatments
Official title: Using Inorganic Chemistry to Understand and Solve Health-Related Problems
Funded at University of California Santa Cruz · NIH-11348146 · Data updated 2026-11-12
Aims to build a chemical program using inorganic compounds to create medicinal solutions, including a potential antidote for carbon monoxide poisoning and improved understanding of antimony-based drugs for leishmaniasis.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California Santa Cruz NIH-funded |
| Lab location | 1 site (Santa Cruz, United States) |
| Project start | July 1, 2024 |
| Project end | June 30, 2029 |
| Funding year | 2026 |
| Award (this year) | $374,411 |
| NIH project number | 5R35GM154824-03 |
| Project ID | NIH-11348146 on NIH RePORTER |
Who could benefit from this research
✓Could help
Individuals at risk of carbon monoxide poisoning or affected by leishmaniasis may benefit from future therapies developed through this program.
✕Less likely to help
Early-stage research may not directly benefit patients in the short term.
What this research studies
This grant funds a program that uses inorganic chemistry to develop medicines that could help people with carbon monoxide poisoning and neglected tropical diseases like leishmaniasis. The research will explore how inorganic compounds can offer new ways to treat these conditions beyond traditional organic chemistry. The project will involve collaborations and building a foundation for future therapies that rely on metal-containing molecules and novel reactivities. If successful, it could lead to safer antidotes and better treatments for patients affected by these diseases.
Why it matters
Potential benefit: Could lead to faster, more effective antidotes for carbon monoxide poisoning and improved treatments for leishmaniasis.
How similar studies have gone: Prior work suggests inorganic chemistry can yield novel medicinal approaches, but the specific antidote and antimony-based therapies are still in early development.
Where this research is happening
-
University of California Santa Cruz
Santa Cruz, United States Active
Researchers
- Principal investigator: Johnstone, Timothy Charles — University of California Santa Cruz
- Study coordinator: Johnstone, Timothy Charles
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.